Incremental effects, costs, and cost effectiveness of the new strategy for detection and surveillance of CRC patients and relatives compared with the current strategy (detected for carrying a deleterious mutation that predisposes for HNPCC)
| CRC patients | Children and siblings | |
|---|---|---|
| Overall incremental costs per life year gained: €2184. | ||
| Extra HNPCC mutation carriers detected (%) | 1.9 | 1 |
| Incremental screening costs (€) | 141 | 9 |
| Incremental costs/mutation carrier detected (€) | 7330 | 950 |
| Incremental surveillance costs (€) | 1927 | 1675 |
| Life years gained | 2.5 | 3 |
| Incremental costs per life year gained (€) | 3801 | 855 |